Buscar
Mostrando ítems 1-10 de 137
Anticoagulation in the antiphospholipid syndrome
(Ferrata Storti Foundation, 2004-01)
Our objectives were to evaluate thrombotic complications in patients with lupus anticoagulant fulfilling Sapporo criteria, anticoagulated with an intended INR 2.0-3.0 due to venous and arterial thrombosis. In our series ...
The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
(Wiley Blackwell Publishing, Inc, 2003-05)
Nojima et al (2002) recently reported the co-existence of lupus anticoagulant (LA) and anti-prothrombin antibodies as a risk factor for the prevalence of acquired activated protein C resistance (APCR) in systemic lupus ...
Platelet function in patients with lupus anticoagulant and thrombosis
(Universidad del Zulia, 2013)
Diluted Bothrops Atrox Time (Dbat). A New Assay to Detect Lupus AnticoagulantValidación del Nuevo Ensayo Tiempo de Bothrops atrox diluido (dBat) para la Detección de Anticoagulante Lúpico
(Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana, 2000)
Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome
(SAGE PUBLICATIONS LTD, 2011)
Antiphospholipid syndrome (APS) is a disorder of coagulation that causes thrombosis as well as pregnancy-related complications, occurring due to the autoimmune production of antibodies against phospholipid. Full anticoagulation ...
Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
(Universidad del RosarioToxicología ClínicaFacultad de Medicina, 2016)
Antiphospholipid syndrome (APS) is an autoimmune disorder characterised by hypercoagulability requiring anticoagulant therapy as the basis, with warfarin as the treatment of choice in cases requiring long-term management. ...
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)
(BMJ Publishing Group, 2018)
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should ...
Avaliação do desempenho dos reagentes do tempo de tromboplastina parcial ativada utilizados para detectar o anticoagulante lúpico
(Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia, 2005-06-01)
INTRODUÇÃO: O anticoagulante lúpico é uma imunoglobulina pertencente à família dos anticorpos antifosfolípides. A sua ação in vitro é interferir nos testes de coagulação dependentes de fosfolípides. O tempo de tromboplastina ...